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S
ince its deorphanization in 2003 (1,2), the fatty
acid receptor GPR40 (FFAR1/FFA1) has drawn
considerable attention as a potential therapeutic
target for type 2 diabetes. Because fatty acids
acutely amplify insulin secretion only in the presence of
glucose, the discovery of a “drugable” cell surface receptor
whose activation glucose-dependently enhances insulin
release generated much interest in the pharmaceutical
industry. The study by Nagasumi et al. (3) in this issue of
Diabetes provides support for the notion that activation of
GPR40 improves glucose tolerance and may thereby be
beneﬁcial for the treatment of type 2 diabetes.
GPR40 is a G protein–coupled receptor highly ex-
pressed in -cells and activated by long-chain fatty acids
(1,2). Loss of function of GPR40 via small interfering RNA
(2,4–6), antisense oligonucleotides (7), pharmacological
inhibition (8), or gene deletion (9,10) has shown that
GPR40 mediates, at least in part, fatty acid potentiation of
glucose-induced insulin secretion. Although the role of
GPR40 in the acute effects of fatty acid is relatively well
established, its potential contribution to chronic deleteri-
ous effects of fatty acids on -cell function has remained
controversial. This question has important implications
because a potential contribution of GPR40 to -cell dys-
function would preclude the development of GPR40 ago-
nists as therapeutic agents. Nagasumi et al. (3) generated
a transgenic mouse overexpressing the human GPR40
gene under the mouse insulin II promoter (hGPR40 trans-
genic mice). GPR40 overexpression did not affect the
metabolic status of the animals under fed conditions, but
it was associated with lower fasting blood glucose.
hGPR40 transgenic mice showed markedly improved oral
glucose tolerance and insulin secretion without changes in
insulin tolerance. These results contradict those of
Steneberg et al. (9), who reported that GPR40 knockout
mice were protected from high-fat diet–induced insulin
resistance and glucose intolerance and that overexpres-
sion of GPR40 under the pancreatic and duodenal ho-
meobox factor 1 (PDX-1) promoter led to impaired insulin
secretion and diabetes. These authors concluded that
excessive activation of GPR40, either by high-fat diet or
overexpression of the receptor, is detrimental to -cell
function (9). Similar ﬁndings were obtained by another
group using a different knockout strain (11). In contrast,
subsequent studies also using whole-body knockout found
that GPR40 deletion did not protect mice from high-fat
diet–induced glucose intolerance (12,13). This conclusion
was further supported by the observation that small-
molecule GPR40 agonists improved glucose tolerance in
mice with high-fat diet–induced obesity (14).
Why such extreme discrepancies? We see three possible
reasons for the differences in phenotypes of transgenic mice
between the study of Steneberg et al. (9) and that of
Nagasumi et al. (3). First, the levels of overexpression of the
receptor were different: 20- to 100-fold in Steneberg et al. (9)
versus 10-fold in Nagasumi et al. (3). Second, the PDX-1
promoter used by Steneberg et al. (9) also drives expression
in non--cells, whereas expression of the mouse insulin II
promoter is essentially restricted to -cells. However, it has
not been conclusively ruled out that these promoters also
have activity in the hypothalamus, which could inﬂuence the
transgenic phenotype. Finally, it is conceivable that trans-
genic expression during embryonic development under the
PDX-1 promoter might have affected islet morphogenesis.
Indeed, the transgenic line in the Steneberg et al. (9) study
showed disorganized islet architecture and decreased insulin
content (9), whereas Nagasumi et al. (3) did not observe
changes in islet morphology or -cell mass. Less clear to us
are the reasons for the differences in the responses to high-fat
diet among different GPR40 knockout lines reported in the
literature, although we suspect the genetic background to be
a critical variable.
Nagasumi et al. (3) further showed that GPR40 overex-
pression prevents the development of hyperglycemia in high-
fat diet–fed hGPR40 transgenic mice. Expression of the
transgene in the diabetic KK background resulted in im-
proved insulin secretion and glucose tolerance without
changes in body weight. These ﬁndings raise three important
points. First, overexpression of GPR40 is sufﬁcient to restore
insulin secretion in a diabetic model. Second, it does not
appear to induce lipotoxicity. This is consistent with our
previous observation, that islets from GPR40 knockout mice
are not protected from fatty acid inhibition of insulin secre-
tion after prolonged exposure (10), and with that of Tan et al.
(14), who showed that culture of islets in the presence of a
GPR40 agonist does not impair insulin secretion. Third, the
data from Nagasumi et al. (3) support a role for GPR40 in the
mechanisms of -cell compensation for insulin resistance.
Consistent with our observation that GPR40 knockout mice
on a high-fat diet develop fasting hyperglycemia sooner than
their wild-type littermates (12), Nagasumi et al. (3) now
demonstrate that overexpression of the receptor enables
-cells to more effectively compensate for insulin resistance.
This has important implications for our understanding of the
pathogenesis of -cell failure (Fig. 1). Based on their obser-
vations, Steneberg et al. (9) suggested that chronic fatty
acid–induced hyperinsulinemia induces insulin resistance,
which is prevented by GPR40 deletion (Fig. 1A). In contrast,
the results of Nagasumi et al. (3) and others (12–14) support
the notion that fatty acid–induced hyperinsulinemia repre-
sents a mechanism by which the -cell compensates for
insulin resistance and that this ability is compromised by
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ported by the observation that a loss-of-function mutation of
the GPR40 gene in humans is associated with altered insulin
secretion (15). Although the validity of therapeutic ap-
proaches consisting of enhancing insulin secretion in type 2
diabetes is a matter of debate (16), we believe that most
available evidence, including the study discussed herein (3),
favors the view that GPR40-mediated fatty acid induction of
insulin secretion is part of the -cell compensatory response.
In conclusion, the study by Nagasumi et al. (3) supports
the concept that activation of GPR40 might be a suitable
therapeutic strategy to improve insulin secretion and
glucose tolerance in type 2 diabetes. Clearly, several
questions remain to be answered before GPR40 agonists
further progress down the path of drug development. First,
prolonged activation of the receptor may lead to down-
regulation and loss of potency. Second, the mechanisms of
action of GPR40 remain to be fully characterized. Third,
GPR40 expression has been detected in non--cells, e.g.,
ileum (1,2), monocytes (1), pancreatic -cells (17), some
areas of the brain (1,18), entero-endocrine cells (19), and
osteoclasts (20), and its function in these tissues is essen-
tially unknown. Finally, the potential contribution of other
long-chain fatty acid receptors expressed in the -cell
remains to be examined.
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FIG. 1. Two alternative hypotheses on the mechanisms behind lipid-
induced insulin resistance and -cell compensation. A: According to
Steneberg et al. (9), the GPR40-mediated increase in insulin secretion
in response to high-fat diet causes insulin resistance. B: In contrast,
previous reports (12,13,15) and the ﬁndings of Nagasumi et al. (3)
suggest that the lipid-induced GPR40-mediated increase in insulin
secretion contributes to -cell compensation for insulin resistance.
FA, fatty acid.
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